Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is a clinical stage biopharmaceutical company that regularly issues news about its precision oncology pipeline and Generative Phosphoproteomics AP3 platform. Company announcements describe progress for its lead CHK1/CHK2 inhibitor ACR-368 in a registrational-intent Phase 2 or Phase 2b trial in endometrial cancer, as well as updates on ACR-2316, a WEE1/PKMYT1 inhibitor in Phase 1 development, and AP3-enabled preclinical programs such as the CDK11-targeting candidate ACR-6840.
News releases from Acrivon often cover interim clinical data, including response rates and tumor shrinkage in AP3-prioritized solid tumor types, details on dose-escalation cohorts, and observations of drug target engagement based on AP3 profiling. The company also reports on regulatory designations, such as FDA Fast Track status for ACR-368 monotherapy in endometrial cancer and FDA Breakthrough Device designation for the ACR-368 OncoSignature assay, as well as trial design elements like biomarker-selected and biomarker-unselected arms and combinations with ultra-low dose gemcitabine.
Investors and observers following ACRV news can expect updates on Acrivon’s presentations at scientific conferences, including AACR and AACR-NCI-EORTC, where the company highlights AP3-based mechanistic data, the AP3 KaiSR generative AI model, and pharmacodynamic insights for ACR-2316 and other candidates. The company also issues periodic financial results and business highlights, summarizing cash resources, research and development activities, and anticipated clinical and regulatory milestones for its AP3-enabled pipeline.
This ACRV news page aggregates these press releases and related coverage, providing a centralized view of Acrivon’s reported clinical progress, platform developments, and corporate updates over time.
Acrivon Therapeutics announced that CEO Peter Blume-Jensen will join a panel on ovarian cancer at the Cowen 43rd Annual Health Care Conference on March 8, 2023, discussing ACR-368, a DNA Damage Response inhibitor in clinical testing for platinum-resistant advanced ovarian cancer.
The Phase 2 trial evaluates ACR-368 in patients with confirmed platinum-resistant ovarian cancer, who have had up to six prior therapies. Patients will be assigned to treatment arms based on results from the OncoSignature® predictive test. Acrivon aims to demonstrate the drug's anti-tumor activity and its potential in combination with gemcitabine.
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) has announced the pricing of its initial public offering (IPO), offering 7,550,000 shares at $12.50 each, targeting gross proceeds of about $99.4 million. A concurrent private placement of 400,000 shares will occur with existing stockholder Chione Limited. The IPO is set to begin trading on Nasdaq on November 15, 2022, closing on November 17, 2022, pending customary conditions. Acrivon is focused on precision oncology treatments backed by its proprietary AP3 platform, and its lead candidate ACR-368 is in a Phase 2 trial.